Want to see HK:3681 full AI Analyst Report?
3681 Stock Chart & Stats
HK$1.39
-HK$0.01(-1.00%)
At close: 4:00 PM EST
HK$1.39
-HK$0.01(-1.00%)
Day’s Range― - ―
52-Week RangeHK$0.99 - HK$3.76
Previous CloseN/A
Volume24.00K
Average Volume (3M)6.26M
Market Cap
HK$1.49B
Enterprise ValueHK$1.19B
Total Cash (Recent Filing)HK$382.40M
Total Debt (Recent Filing)HK$338.64M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding1,386,638,300
10 Day Avg. Volume8,278,616
30 Day Avg. Volume6,255,789
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.91
Price to Sales (P/S)0.00
P/FCF Ratio-15.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)HK$8.71M
Bulls Say, Bears Say
Bulls Say
Focused Monoclonal Antibody R&DA clear, specialized R&D focus on therapeutic monoclonal antibodies and immunology/inflammatory indications provides durable strategic clarity. This specialization supports deep technical expertise, more efficient pipeline prioritization, and relevance to enduring clinical demand for biologics, improving long-term development odds and partner interest.
Improved Leverage And Stronger Capital Structure In 2025Material leverage improvement in 2025 reduces near-term refinancing pressure and improves financial flexibility. A lower debt burden and higher equity position lengthen runway and make funding future clinical stages less vulnerable to tightening credit, supporting continuity of R&D programs over the coming months.
Commercialization Via Strategic PartnershipsA stated commercialization strategy that includes strategic partners is structurally advantageous for a development-stage biotech. Partnering can accelerate market entry, reduce capex and commercial staffing needs, and transfer commercialization risk, enabling the company to focus capital on R&D and de-risk late-stage programs.
Bears Say
Revenue Collapsed To Zero In 2025Reported revenue of zero in 2025 is a durable warning that the company currently lacks commercialized products and meaningful operating income. Absent product revenue, the business remains dependent on financing events or licensing deals to fund operations, increasing execution and funding risk over the medium term.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow means the company burns cash to sustain R&D and operations. This structural cash deficit shrinks runway, forces periodic external financing or dilutive capital raises, and can delay or scale back clinical programs if funding conditions tighten over the next several months.
Ongoing Net Losses And Deeply Negative Returns On CapitalPersistent net losses and negative returns on capital indicate the business is not generating shareholder value from invested resources. This undermines long-term sustainability, can raise the cost of future capital, and pressures management to pursue dilutive financings or asset sales if clinical progress does not translate into revenue.
SinoMab Bioscience Ltd. News
3681 FAQ
What was SinoMab Bioscience Ltd.’s price range in the past 12 months?
SinoMab Bioscience Ltd. lowest stock price was HK$0.99 and its highest was HK$3.76 in the past 12 months.
What is SinoMab Bioscience Ltd.’s market cap?
SinoMab Bioscience Ltd.’s market cap is HK$1.49B.
When is SinoMab Bioscience Ltd.’s upcoming earnings report date?
SinoMab Bioscience Ltd.’s upcoming earnings report date is Aug 24, 2026 which is in 50 days.
How were SinoMab Bioscience Ltd.’s earnings last quarter?
SinoMab Bioscience Ltd. released its earnings results on Mar 23, 2026. The company reported -HK$0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.044.
Is SinoMab Bioscience Ltd. overvalued?
According to Wall Street analysts SinoMab Bioscience Ltd.’s price is currently Overvalued.
Does SinoMab Bioscience Ltd. pay dividends?
SinoMab Bioscience Ltd. does not currently pay dividends.
What is SinoMab Bioscience Ltd.’s EPS estimate?
SinoMab Bioscience Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SinoMab Bioscience Ltd. have?
SinoMab Bioscience Ltd. has 1,386,638,300 shares outstanding.
What happened to SinoMab Bioscience Ltd.’s price movement after its last earnings report?
SinoMab Bioscience Ltd. reported an EPS of -HK$0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.183%.
Which hedge fund is a major shareholder of SinoMab Bioscience Ltd.?
Currently, no hedge funds are holding shares in HK:3681
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SinoMab Bioscience Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.64%
12-Months-Change
Fundamentals
Return on Equity
-27.70%
Trailing 12-Months
Asset Growth
26.20%
Trailing 12-Months
Company Description
SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biopharmaceutical enterprise that specializes in the comprehensive process of discovering, developing, producing, and marketing therapeutic solutions for various immunological disorders. Their approach predominantly involves monoclonal antibody (mAb)-based biologics. A key asset in their portfolio is SM03, an innovative anti-CD22 monoclonal antibody. This drug is currently in Phase III clinical trials for rheumatoid arthritis (RA), with additional clinical investigations underway for other immune-related conditions such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company is also progressing with SN1011, a Bruton's tyrosine kinase inhibitor. This compound is in Phase II clinical trials for pemphigus and has commenced Phase I trials for multiple sclerosis, SLE, and neuromyelitis optica spectrum disorder (NMOSD). Furthermore, SinoMab maintains an active preclinical pipeline. This includes SM17, which targets asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06, intended for RA, SLE, NMOSD, and SS; SM09, in development for NHL and RA; and TNF2, focused on a range of autoimmune diseases. Founded in 2001, SinoMab BioScience Limited is based in Pak Shek Kok, Hong Kong, and conducts its business activities across Mainland China, the Cayman Islands, and Hong Kong.
Technical Analysis
Genor Biopharma Holdings Limited
―
Alphamab Oncology
―
Mabpharm Limited
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―